COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?

Area of Science:

• Oncology
• Molecular Biology
• Pathology

Background:

• Anaplastic thyroid carcinoma (ATC) and angiosarcoma of the thyroid (AST) are aggressive cancers with limited treatment options.
• Cyclooxygenase-2 (COX-2) inhibition has shown potential in suppressing tumor growth.
• Investigating COX-2 expression in ATC and AST is crucial for identifying new therapeutic strategies.

Purpose of the Study:

• To investigate the protein expression of COX-2 in anaplastic thyroid carcinoma (ATC) and angiosarcoma of the thyroid (AST).
• To determine if strong COX-2 expression correlates with potential therapeutic responses to COX-2 inhibitors.

Main Methods:

• Immunohistochemistry was used to assess COX-2 protein expression in 26 ATC and 26 AST cases.
• Tumor samples were analyzed for the presence and intensity of COX-2 expression.

Main Results:

• COX-2 expression was detected in 50% of ATC cases and 42% of AST cases.
• Strong COX-2 expression (in >50% of tumor cells) was observed in approximately 20% of both ATC and AST samples.
• Two cases with partial or complete remission in a prior celecoxib trial had tumors with strong COX-2 expression.

Conclusions:

• A subset of ATC and AST patients exhibit strong COX-2 expression.
• This finding suggests that COX-2 inhibitors, such as celecoxib, might be a viable therapeutic option for select patients with these aggressive thyroid malignancies.
• Further research is warranted to explore the efficacy of COX-2 inhibitors in these patient populations.